NX Development Corp | Finanzwire

Basculer en Français

10936	Companies
238805	Keywords
167666	Articles
128365	Press releases

Home
Companies
NX Development Corp

BRIEF

published on 06/21/2024 at 15:05, 2 years 2 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

Gleolan NX Development Corp. OVA-302 Study FDA Orphan Designation
PRESS RELEASE

published on 06/21/2024 at 15:00, 2 years 2 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. enrolls first patient in OVA-302 study for cancer management using Gleolan following FDA's Orphan Designation. CEO DeSena and Chairman Kosciessa express excitement for future programs

Gleolan NX Development Corp. OVA-302 Study Cancer Management Flourescence-guided Surgery
BRIEF

published on 03/05/2024 at 23:05, 2 years 5 months ago

NX Development Corp. Awarded Orphan-Drug Designation for Gleolan in Ovarian Cancer Treatment

FDA NX Development Corp Orphan-Drug Designation Gleolan Ovarian Cancer
PRESS RELEASE

published on 03/05/2024 at 23:00, 2 years 5 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery

FDA Cancer Care Gleolan NX Development Corp. Orphan-drug Status

Accesswire

Published on 09/04/2026 at 23:30, 4 hours 33 minutes ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 5 hours 3 minutes ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 5 hours 33 minutes ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 13 hours 33 minutes ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/04/2026 at 14:00, 14 hours 3 minutes ago

Horizon Aircraft Appoints Tom Hearne to Board of Directors and Names Him Audit Committee Chair

View all ACCESSWIRE

EQS Group

Published on 09/04/2026 at 22:10, 5 hours 53 minutes ago

Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 8 hours 43 minutes ago

Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:55, 9 hours 8 minutes ago

Holding(s) in Company
Published on 09/04/2026 at 18:50, 9 hours 13 minutes ago

A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 9 hours 58 minutes ago

Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership

Les Echos

Published on 09/04/2026 at 18:57, 9 hours 6 minutes ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 10 hours 18 minutes ago

Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 10 hours 18 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 12 hours 3 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 12 hours 3 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026

View all LES ECHOS COMFI WIRE